

4 weeks between doses 1 and 2 for HepB and HepA-HepB; between doses 2 and 3, 8 weeks for HepB and 5 months for HepA-HepB).

Special populations

- Administer HepB or HepA-HepB to adults with the following indications:
 - **Chronic liver disease** (e.g., hepatitis C infection, cirrhosis, fatty liver disease, alcoholic liver disease, autoimmune hepatitis, alanine aminotransferase [ALT] or aspartate aminotransferase [AST] level greater than twice the upper limit of normal)
 - **HIV infection**
 - **Percutaneous or mucosal exposure to blood** (e.g., household contacts of hepatitis B surface antigen [HBsAg]-positive persons; adults younger than age 60 years with diabetes mellitus or age 60 years or older with diabetes mellitus based on individual clinical decision; adults in predialysis care or receiving hemodialysis or peritoneal dialysis; recent or current injection drug users; healthcare and public safety workers at risk for exposure to blood or blood-contaminated body fluids)
 - **Sexual exposure risk** (e.g., sex partners of HBsAg-positive persons; sexually active persons not in a mutually monogamous relationship; persons seeking evaluation or treatment for a sexually transmitted infection; and men who have sex with men [MSM])
 - Receiving care in **settings where a high proportion of adults have risks for hepatitis B infection** (e.g., facilities providing sexually transmitted disease treatment, drug-abuse treatment and prevention services, hemodialysis and end-stage renal disease programs, institutions for developmentally disabled persons, healthcare settings targeting services to injection drug users or MSM, HIV testing and treatment facilities and correctional facilities)
 - **Travel** to countries with high or intermediate hepatitis B endemicity

10. Meningococcal vaccination (www.cdc.gov/vaccines/hcp/acip-recs/vacc-specific/mening.html)

Special populations: Serogroup A, C, W, and Y meningococcal vaccine (MenACWY)

- Administer 2 doses of MenACWY at least 8 weeks apart and revaccinate with 1 dose of MenACWY every 5 years, if the risk remains, to adults with the following indications:
 - **Anatomical or functional asplenia** (including sickle cell disease and other hemoglobinopathies)
 - **HIV infection**
 - **Persistent complement component deficiency**
 - **Eculizumab use**
- Administer 1 dose of MenACWY and revaccinate with 1 dose of MenACWY every 5 years, if the risk remains, to adults with the following indications:
 - **Travel to or live in countries where meningococcal disease is hyperendemic or epidemic**, including countries in the African meningitis belt or during the Hajj
 - At risk from a **meningococcal disease outbreak attributed to serogroup A, C, W, or Y**
 - **Microbiologists** routinely exposed to *Neisseria meningitidis*
 - **Military recruits**
 - **First-year college students who live in residential housing** (if they did not receive MenACWY at age 16 years or older)

General information: Serogroup B meningococcal vaccine (MenB)

- May administer, based on individual clinical decision, to young adults and adolescents age 16–23 years (preferred age is 16–18 years) who are not at increased risk 2-dose series of MenB-4C (Bexsero) at least 1 month apart or 2-dose series of MenB-FHbp (Trumenba) at least 6 months apart
- MenB-4C and MenB-FHbp are not interchangeable.

Special populations: MenB

- Administer 2-dose series of MenB-4C at least 1 month apart or 3-dose series of MenB-FHbp at 0, 1–2, and 6 months to adults with the following indications:
 - **Anatomical or functional asplenia** (including sickle cell disease)
 - **Persistent complement component deficiency**
 - **Eculizumab use**
 - At risk from a **meningococcal disease outbreak attributed to serogroup B**
 - **Microbiologists** routinely exposed to *Neisseria meningitidis*

11. *Haemophilus influenzae* type b vaccination (www.cdc.gov/vaccines/hcp/acip-recs/vacc-specific/hib.html)

Special populations

- Administer *Haemophilus influenzae* type b vaccine (Hib) to adults with the following indications:
 - **Anatomical or functional asplenia** (including sickle cell disease or undergoing elective splenectomy: Administer 1 dose if not previously vaccinated (preferably at least 14 days before elective splenectomy).
 - **Hematopoietic stem cell transplant (HSCT)**: Administer 3-dose series with doses 4 weeks apart starting 6 to 12 months after successful transplant regardless of Hib vaccination history.

Additional resources for healthcare providers include:

- ▶ Details on vaccines recommended for adults and complete ACIP statements are available at www.cdc.gov/vaccines/hcp/acip-recs/index.html
- ▶ Vaccine Information Statements that explain benefits and risks of vaccines are available at www.cdc.gov/vaccines/hcp/vis/index.html
- ▶ Information and resources on vaccinating pregnant women are available at www.cdc.gov/vaccines/adults/rec-vac/pregnant.html
- ▶ Information on travel vaccine requirements and recommendations is available at www.cdc.gov/travel/destinations/list
- ▶ CDC Vaccine Schedules App for immunization service providers to download is available at www.cdc.gov/vaccines/schedules/hcp/schedule-app.html
- ▶ Adult Vaccination Quiz for self-assessment of vaccination needs based on age, health conditions, and other indications at www2.cdc.gov/nip/adultimmsched/default.asp
- ▶ *Recommended Immunization Schedule for Children and Adolescents Aged 18 Years or Younger* is available at www.cdc.gov/vaccines/schedules/hcp/child-adolescent.html